Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gunilla Osswald"'
Autor:
Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Nicolas Fritz, Olof Zachrisson, Adeline Rachalski, Anne-Sophie Svensson, Emily Button, Giacomo Dentoni, Gunilla Osswald, Lars Lannfelt, Christer Möller
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with ed
Externí odkaz:
https://doaj.org/article/67066c16a067456492ca854e513c78f6
Autor:
Eva Nordström, Fredrik Eriksson, Jessica Sigvardson, Malin Johannesson, Alex Kasrayan, Martina Jones-Kostalla, Paulina Appelkvist, Linda Söderberg, Patrik Nygren, Magdalena Blom, Adeline Rachalski, Karin Nordenankar, Olof Zachrisson, Ebba Amandius, Gunilla Osswald, Mikael Moge, Martin Ingelsson, Joakim Bergström, Lars Lannfelt, Christer Möller, Marco Giorgetti, Johanna Fälting
Publikováno v:
Neurobiology of Disease, Vol 161, Iss , Pp 105543- (2021)
A growing body of evidence suggests that aggregated α-synuclein, the major constituent of Lewy bodies, plays a key role in the pathogenesis of Parkinson's disease and related α-synucleinopathies. Immunotherapies, both active and passive, against α
Externí odkaz:
https://doaj.org/article/707d9ab628d84f509f885d36c2242dcb
Autor:
Fredrik Eriksson, Linda Söderberg, Johanna Fälting, Magdalena Blom, Jessica Sigvardson, Karin Nordenankar, Alex Kasrayan, Paulina Appelkvist, Lars Lannfelt, Malin Johannesson, Marco Giorgetti, Ebba Amandius, Eva Nordström, Adeline Rachalski, Olof Zachrisson, Martin Ingelsson, Gunilla Osswald, Martina Jones-Kostalla, Mikael Moge, Patrik Nygren, Christer Möller, Joakim Bergström
Publikováno v:
Neurobiology of Disease, Vol 161, Iss, Pp 105543-(2021)
A growing body of evidence suggests that aggregated alpha-synuclein, the major constituent of Lewy bodies, plays a key role in the pathogenesis of Parkinson's disease and related alpha-synucleinopathies. Immunotherapies, both active and passive, agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb10ba3c58fd067b8ef68b07c6c11213
http://www.sciencedirect.com/science/article/pii/S0969996121002928
http://www.sciencedirect.com/science/article/pii/S0969996121002928
Publikováno v:
Drug discovery today. 25(6)
Scientists increasingly find themselves working in bilateral drug development alliances. Alliances are conceptually simple, but operationally challenging, resulting in the value-eroding misalignment and delays that alliances often experience. This ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbb2d6b8aadfc612d4a8ea1b20467d4
https://pubmed.ncbi.nlm.nih.gov/32173523
https://pubmed.ncbi.nlm.nih.gov/32173523
Autor:
Andrew Satlin, Hans Basun, Lars Lannfelt, Gunilla Osswald, Robert Lai, Veronika Logovinsky, June Kaplow, Chad J. Swanson
Publikováno v:
Alzheimer's Research & Therapy
Background Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. Methods Here we des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2cec51c080e02a96ac7395a6a084fe8
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-294671
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-294671
Autor:
Linda Söderberg, Stina Tucker, Hanna Laudon, Gunilla Osswald, Christer Möller, Erika Spens, Andrew Satlin, Pär Gellerfors, Erik Rollman Waara, Charlotte Sahlin, Johan Sjödahl, Lars Lannfelt, Anna Lord, Karin Tegerstedt
Publikováno v:
Journal of Alzheimer's disease : JAD. 43(2)
Amyloid-beta (A beta) immunotherapy for Alzheimer's disease (AD) has good preclinical support from transgenic mouse models and clinical data suggesting that a long-term treatment effect is possible. Soluble A beta protofibrils have been shown to exhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45fab5b041d7f598ce68ffcf4b24a4dd
https://pubmed.ncbi.nlm.nih.gov/25096615
https://pubmed.ncbi.nlm.nih.gov/25096615
Autor:
Hans Basun, Christer Möller, Dag Sehlin, Veronika Logovinsky, Gunilla Osswald, Lars Lannfelt, Andrew Satlin, Pär Gellerfors
Publikováno v:
Alzheimer's Research & Therapy
The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae9dc68386f9af7f3c4901109b34fab
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-231496
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-231496
Autor:
Sven Hellberg, Stefan von Berg, P.A. Schött, Ratan Bhat, Anita Andersson, Anette Mörtberg, Susanne Gruber, Johan Sandin, Biljana Georgievska, Jan A.M. Neelissen, Per I. Arvidsson, Gunilla Osswald, Johanna Fälting, Yvonne Nilsson, James J. Doherty
Publikováno v:
Journal of neurochemistry. 125(3)
Abnormal tau phosphorylation resulting in detachment of tau from microtubules and aggregation are critical events in neuronal dysfunction, degeneration, and neurofibrillary pathology seen in Alzheimer's disease. Glycogen synthase kinase-3β (GSK3β)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1d02e135ec312ce2746adc21c8a02e
https://pubmed.ncbi.nlm.nih.gov/23410232
https://pubmed.ncbi.nlm.nih.gov/23410232
Autor:
Meindert Danhof, Margareta Hammarlund-Udenaes, Piet H. van der Graaf, Jasper Stevens, Gunilla Osswald, Bart A. Ploeger, Elizabeth C. M. de Lange
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 39(5)
The aim of this investigation was to develop a mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) model for the biological system prolactin response following a dopamine inhibition challenge using remoxipride as a paradigm compound. After assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287d6f1e07bcd287cbfd5e875fef6ad3
https://pubmed.ncbi.nlm.nih.gov/22791078
https://pubmed.ncbi.nlm.nih.gov/22791078
Publikováno v:
Cerebrovascular Diseases. 8:188-190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7594ed6d830c53a12ad7b31da7624587
https://doi.org/10.1159/000015846
https://doi.org/10.1159/000015846